MULTIFUNCTIONAL RNA MOLECULES TO TREAT EWING SARCOMA
Lack of prevention and effective treatments of Ewing Sarcoma (ES)
New conjugate to suppress ES progressive and metastasis capacity
• New effective treatment for ES and other sarcomas
• Multifunctional RNA conjugate targeting Ewing Sarcoma metastasis
This technology will be mainly directed to treat Ewing Sarcoma.
Nevertheless, it could also be used in alveolar rhabdomyosarcomas (ARMS) and other sarcomas, since they area characterized by the presence of another chromosomal translocationand also have elevated levels of EphA2 receptor.
Its therapeutic efficacy has been demonstrated in vitro in cell lines and is being demonstrated in vivo in animal models. The group also has proposed the possibility of expanding the use of the conjugate using different siRNAs against the fusion proteins characteristic of these sarcomas.
The therapeutic efficacy of the conjugate is being tested in an orthotopic ES model. The reproducibility of the conjugate in the ARMS is also being tested.
TRL: Animal Model Validation
IP: Patent in process